AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer|NSCLC, Squamous or Non-Squamous|Urothelial Carcinoma of the Bladder|Microsatellite Stable (MSS) Colorectal Cancer (CRC)|Cervical Cancer
Interventions: DRUG: AN0025|DRUG: Pembrolizumab
Sponsor: Adlai Nortye Biopharma Co., Ltd.
Collaborators: Merck Sharp & Dohme LLC